You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)

    SBC: Mulberry Biotherapeutics, Inc.            Topic: NINDS

    Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects about 1 in 25,000 individuals globally. While usually benign, these tumors result in severe morbidity and mortality in affected individuals. Almost all NF2 patients lose their hearing, and many lose the ability to walk and even to see. NF2 patients’ average age at death is 36 years, many of whom die in adolescence or early ad ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. A novel device for cervical insufficiency in pregnant women

    SBC: Cx Therapeutics, Inc            Topic: NICHD

    Abstract In normal pregnancy, the cervix remains closed until term and then dilates under the influence of uterine contractions. In cases of cervical insufficiency (CI), the cervix dilates in the second trimester in the absence of uterine contractions, which leads to a preterm birth. Infants born prematurely are at risk of lifelong morbidities including chronic lung disease, feeding difficulties, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirements

    SBC: PASCALL Systems, Incorporated            Topic: NIDA

    PROJECT SUMMARY In light of the opioid crises, minimizing postoperative pain and postoperative opioid requirements to reduce chronic opioid dependency among surgical patients have become major concerns for surgeons and anesthesiologists. Effective intraoperative nociception control can mitigate these concerns. Unfortunately, existing nociceptive monitoring tools use indicators that are inherently ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss

    SBC: Courage Therapeutics, Inc.            Topic: 300

    Rates of obesity have steadily increased in the United States, with approximately 50 percent of Americans projected to be classified as obese by 2030. Interestingly, obesity even seems to be a risk factor for the severity of illness in response to COVID-19 disease. Although behavioral (dieting and exercise), pharmacological, and surgical approaches exist for weight loss, many individuals who lose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations

    SBC: Photosonox LLC            Topic: NIBIB

    ABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. InheRET: A SaaS solution to identify patients at increased risk for hereditary disease.

    SBC: Inheret, Inc            Topic: NCI

    PROJECT SUMMARY This project is to expand the InheRET Inherited Risk Evaluation Tool to include recommendations for testing of patients at increased risk for hereditary disease, adding patient navigation features and customizable database entries for healthcare providers. This will include the development, integration and testing of InheRET 3.0 followed by pilot testing in 5 diverse clinics. InheR ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Unbiased longitudinal neuromorphometry for clinical decision support

    SBC: CORTICOMETRICS LLC            Topic: NIA

    Project Summary Normal human neuroanatomy is incredibly variable, and increases with age. This impedes the ability of neuroimaging to detect effects in neurological conditions such as Alzheimerandapos;s disease (AD), Huntingtonandapos;s disease (HD), multiple sclerosis (MS) and schizophrenia. Most of the recently available state-of-the-art quantitative imaging tools still use cross-sectional metho ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: ADK Group, LLC            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: Endectra LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD

    SBC: ONL Therapeutics, Inc.            Topic: NEI

    PROJECT SUMMARY / ABSTRACT Age-related macular degeneration (AMD) is the leading, and due to the aging baby boomers, a growing cause of irreversible vision loss in the United States, and is strongly associated with exposure to cigarette smoke (CS) and high fat diets (HFD). While effective treatment is available for neovascular AMD, the AREDS II antioxidant vitamins are the only proven treatment fo ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government